TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A paper in The Lancet Healthy Longevity argues that sarcopenia should be understood as a problem involving the aging motor system, including the brain, nerves and muscles, rather than muscle loss alone. The authors propose changes to research and assessment, but say new measures have not yet been shown to outperform existing screens or improve outcomes.
Researchers writing in The Lancet Healthy Longevity argue that age-related weakness and mobility loss should be understood as changes across the motor system—including the brain, nerves and muscles—not simply as muscle wasting. Their proposal could shift how sarcopenia is studied and assessed, although the authors say the suggested tests and approach still need validation.
Sarcopenia is a substantial loss of muscle strength and physical function associated with aging. The Medical Xpress report says it affects up to 29% of older adults living in the community, with higher rates in hospitals and residential care and among people with multiple health conditions or frailty. The condition contributes to frailty, disability and loss of independence.
The paper’s authors say diagnostic practice has already moved beyond relying on muscle mass alone. Measures such as grip strength, walking speed and chair stands are used because they predict outcomes such as falls, disability and death better than muscle mass does. But, they argue, explanations and treatments have continued to focus mainly on muscle. They say muscle loss accounts for only a modest share of the strength decline seen with age, and people with similar muscle amounts can have markedly different strength and mobility.
The authors describe movement as the result of signals and coordination across the brain, spinal cord, nerves and muscles. Aging may affect movement planning, nerve signals, balance and the sense of body position, they say. They point to standing up from a chair as an example: the task depends on speed and power as well as muscle bulk, and power can decline earlier and faster than muscle mass.
The proposal matters because weakness can limit walking, rising from a chair and carrying out daily tasks, even when muscle loss alone does not explain a person’s difficulties. If the authors’ model is borne out, assessment focused only on muscle may miss other contributors to declining mobility and could steer treatment research too narrowly.
The stakes are especially clear around falls. The source report says Australia recorded 253,800 fall-related hospitalizations in 2024–25. It also reports that 6,722 Australians died following a fall in the preceding year and estimates fall injuries cost the health system A$5.4 billion. These figures provide national context for the consequences of impaired mobility; they do not show that the proposed motor-system approach would prevent falls.
The authors call for research and care to look beyond strategies aimed mainly at increasing muscle mass, toward interventions that improve strength, movement and everyday function. That is a proposed direction, not evidence that a new treatment or screening method is already effective.
Products Worth Considering
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
Levoit Eleva 300X HEPA Air Purifier for Home and Bedroom
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
How Sarcopenia Assessment Has Shifted
Earlier this year, the Australian Journal of General Practice published a proposed algorithm for screening, assessing and managing poor muscle health in primary care, according to Medical Xpress. That work has drawn attention to how general practitioners identify and respond to weakness in older patients.
The new paper by Lucas B. R. Orssatto and colleagues addresses the explanation behind the symptoms. While measures of strength and function have gained importance in diagnosis, the authors say the prevailing account still treats sarcopenia chiefly as a muscle disease. Their publication proposes a wider framework and a five-point agenda for international groups responsible for diagnostic criteria. The source material does not list the full agenda.
The authors suggest clinicians could pay attention to how quickly a patient rises from a chair, unsteadiness during sustained effort, hand dexterity and walking while performing another task, such as talking. They also recommend closer examination when weakness is asymmetric, rapid or out of proportion to apparent muscle loss. These are proposals for attention and assessment, not validated replacements for current screening.
“We propose that sarcopenia is better understood as a disease of the aging motor system.”
— Lucas B. R. Orssatto and colleagues, in their paper in The Lancet Healthy Longevity
Tests and Benefits Still Need Validation
The paper presents a proposed framework, not proof that changing the definition of sarcopenia will improve health outcomes. The authors say no one has yet shown that the additional measures they suggest outperform existing screens in outcomes or cost. They call for practical tests to be validated and for trials to measure effects on nerves as well as muscle.
It also remains unclear how easily primary care teams could adopt more detailed motor-system assessments. The authors note that neuromuscular expertise is not evenly available in primary care. The source report does not provide results from a clinical trial of the proposed approach, or evidence that it reduces falls, disability or health-care costs.
The paper also says sedative and anticholinergic medicines can blunt motor drive and argues that medication review belongs alongside strength training. That is the authors’ clinical recommendation; the material provided does not quantify the effect of these medicines or establish how a medication review would change mobility outcomes for particular patients.
Research Groups Face the Next Steps
The authors are asking international groups that set sarcopenia diagnostic criteria to consider their five-point agenda. The next research steps they identify include validating practical assessments, developing guidelines for a staged approach and running trials that examine nerve function alongside muscle.
Those steps would help determine whether the broader model can be used reliably in ordinary clinical settings and whether it leads to better decisions or outcomes. Until such evidence is available, the proposed assessment additions remain under evaluation, while existing measures of strength and mobility continue to be central to identifying functional decline.
Key Questions
What is the main claim of the new paper?
The authors argue that sarcopenia involves the aging motor system, including the brain, spinal cord, nerves and muscles, rather than muscle loss alone.
Does the paper show that muscle loss is unimportant?
No. The paper does not say muscle is irrelevant. It argues that muscle loss explains only a modest share of age-related strength decline and that other parts of the motor system also need attention.
What assessment changes do the authors suggest?
They suggest looking at how quickly someone rises from a chair, balance during sustained effort, hand dexterity and walking while doing another task. The authors say these measures still need validation and have not been shown to outperform existing screens.
Could this approach prevent falls?
The paper does not establish that the proposed framework prevents falls. Its authors argue that a broader understanding could support better assessment and targeted interventions, but clinical benefits remain unproven.
Source: medicalxpress.com
